Core Insights - Prenetics Global Limited reported a significant revenue growth of 452.1% year-over-year, reaching $32.3 million in the first half of 2025 [1][5] - The company achieved a remarkable monthly revenue of $5.9 million in August 2025 for its IM8 brand, with a compound annual growth rate (CAGR) exceeding 3,100% [1][12] - Prenetics has increased its full-year 2025 revenue guidance to a range of $85 million to $100 million and anticipates reaching break-even by Q1 2026 [1][17] Financial Performance - In Q2 2025, Prenetics generated $17.7 million in revenue, marking a 594.9% increase compared to Q2 2024 [5] - The gross profit for Q2 2025 was $7.3 million, up 233.5% from the same quarter in the previous year [5] - The adjusted EBITDA loss for Q2 2025 was $(4.1) million, a decrease of 8.7% compared to Q1 2025 [5] - The total loss for Q2 2025 was $(10.9) million, reflecting a 22.7% increase from Q2 2024 [5] Business Unit Performance - IM8 generated $9.8 million in revenue for Q2 2025, a 70% increase over Q1 2025 [5] - Europa and CircleDNA contributed $5.7 million and $2.2 million in revenue, respectively, for Q2 2025 [5] - For the first half of 2025, IM8's revenue was $15.5 million, while Europa and CircleDNA generated $12.0 million and $4.8 million, respectively [13] Strategic Initiatives - Prenetics has initiated a disciplined Bitcoin treasury strategy, acquiring a total of 228 Bitcoin, with a daily accumulation of 1 BTC starting August 2025 [1][15] - The company holds a strong cash position of $90 million, including $26.1 million in Bitcoin, and remains debt-free [2][5] - Prenetics aims to enhance shareholder value through its strategic focus on both health and wealth optimization [2] Market Position and Growth Potential - IM8 has positioned itself as one of the fastest-growing supplement brands globally, with over 8 million servings delivered and more than 300,000 customer orders [12][10] - The brand's marketing efforts, including a partnership with Aryna Sabalenka, have significantly increased brand awareness, generating 233 million views during the US Open [10] - The company is optimistic about future product launches that will further solidify IM8's leadership in premium nutrition and longevity solutions [11]

Core Insights - Prenetics Global Limited and its premium supplement brand IM8 celebrate Aryna Sabalenka's successful defense of her US Open title, marking a significant achievement for both the company and the brand [1][2] Company Overview - Prenetics Global Limited (NASDAQ: PRE) is a leading health sciences company focused on advancing consumer health through initiatives like IM8, Europa, and CircleDNA [6][8] - IM8, co-founded by David Beckham, aims to provide premium core nutrition through scientifically backed products [7][8] Product Performance - IM8 Daily Ultimate Essentials, launched in December 2024, has seen over 300,000 customer purchases and delivered more than 6 million servings, indicating strong consumer confidence and satisfaction [3][7] - The product is designed to replace 16 individual supplements, offering 92 essential nutrients and is NSF Certified for Sport, ensuring safety and quality for professional athletes [5][8] Marketing and Brand Promotion - An AI-powered advertisement featuring Aryna Sabalenka has gone viral, achieving over 233 million views on Instagram since August 25, further enhancing brand visibility [3][7] - The advertisement campaign has been prominently displayed on Times Square billboards during the US Open, amplifying IM8's market presence [3][7] Strategic Partnerships - Aryna Sabalenka, who became the first current athlete shareholder of IM8, has integrated IM8 Daily Ultimate Essentials into her training regimen, showcasing the product's effectiveness [2][4] - The partnership with Sabalenka is seen as a validation of IM8's offerings and a strategic move to enhance brand credibility in the competitive health supplement market [4][6]

Core Viewpoint - Honeywell announced a $600 million equity capital raise for Quantinuum, valuing the company at $10 billion pre-money, aimed at advancing quantum computing technology [1][3]. Company Overview - Quantinuum is recognized as the world's highest-performing quantum computer developer, focusing on commercially useful quantum computing solutions [4][11]. - The company employs over 630 staff, including more than 370 scientists and engineers, across multiple countries [11]. Investment and Partnerships - Existing shareholders, including JPMorganChase, Mitsui, and Amgen, along with new investors like MESH and Korea Investment Partners, participated in the funding round [2]. - The capital raise will support the launch of Helios, Quantinuum's next-generation quantum computing system, expected this year [3]. Technological Advancements - Quantinuum aims to achieve universal fault-tolerant computing, enhancing its leadership in the quantum computing sector [3]. - The company is collaborating with NVIDIA on breakthroughs at the NVIDIA Accelerated Quantum Research Center [5]. Strategic Collaborations - Quantinuum has formed partnerships with organizations such as RIKEN, SoftBank Corp., and Infineon to expand its quantum computing capabilities [5]. - A joint venture in Qatar will deliver advanced quantum computing infrastructure as part of a $1 billion investment over the next decade [6]. Market Impact - The company's solutions are driving scientific discoveries, economic growth, and sustainable development, positioning it as a leader in the quantum technologies industry [4][6]. - Quantinuum's advancements are expected to enhance classical artificial intelligence capabilities and contribute to next-generation technologies [5].

Core Insights - Prenetics Global Limited announced a partnership between its premium supplements brand IM8 and world No. 1 tennis player Aryna Sabalenka, who becomes the brand's global ambassador and shareholder [1][6][12] - This partnership is significant as it marks the first endorsement of a supplement brand by Sabalenka, who has reported substantial benefits from using IM8's Daily Ultimate Essentials [3][4][5] Company Overview - Prenetics is a leading consumer health sciences company listed on NASDAQ under the ticker PRE, focusing on advancing consumer health through various initiatives, including IM8 [10] - IM8, co-founded by David Beckham, has rapidly grown to generate over US$50 million in Annual Recurring Revenue within just six months of its launch [6][8] - IM8 has built a loyal customer base of over 60,000 users, delivering more than 5 million servings of its products [6][8] Product Details - IM8's flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements with a single, NSF Certified for Sport® powder supplement [11] - The product is non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors, or sweeteners [11] Market Context - The partnership comes at a time when supplement safety and quality are critical issues in professional sports, with IM8's NSF Certified for Sport® designation ensuring rigorous testing for prohibited substances [7] - IM8's revenue growth trajectory exceeds typical benchmarks for successful supplement launches by 500%, indicating strong market demand and acceptance [8]

Core Insights - Prenetics Global Limited announced a partnership between its premium supplements brand IM8 and world No. 1 tennis player Aryna Sabalenka, who becomes the brand's global ambassador and shareholder [1][6][12] - This partnership is significant as it marks the first endorsement of a supplement brand by Sabalenka, who has reported substantial benefits from using IM8's Daily Ultimate Essentials [3][4][6] Company Overview - Prenetics is a leading consumer health sciences company listed on NASDAQ under the ticker PRE, focusing on advancing consumer health through innovative products [10] - IM8, co-founded by David Beckham, is a rapidly growing health and wellness brand that has achieved over US$50 million in Annual Recurring Revenue within six months of its launch [6][8][11] Product Details - IM8's flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements with a single, NSF Certified for Sport® powder supplement, ensuring safety and efficacy for athletes [11][12] - The product has gained a loyal customer base of over 60,000 users, who have consumed more than 5 million servings [6][8] Market Position - IM8 is recognized as one of the fastest-growing supplement brands globally, with its revenue velocity exceeding typical benchmarks for successful launches by 500% [8] - The partnership with Sabalenka comes at a time when supplement safety and quality are critical issues in professional sports, highlighting the importance of IM8's NSF certification [7][8] Athlete Endorsement - Aryna Sabalenka's personal experience with IM8 has led her to not only endorse the brand but also invest in it, reflecting her confidence in the product's quality and effectiveness [5][7] - The collaboration emphasizes the alignment of Sabalenka's values of athletic excellence and professionalism with IM8's commitment to quality and innovation [7][9]

Core Insights - Prenetics Global Limited has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million purchase of 187.42 BTC at an average price of $106,712 per Bitcoin [2][17] - The company aims to significantly increase its Bitcoin holdings and become one of the largest corporate Bitcoin holders in the healthcare sector, inspired by strategies from MicroStrategy and Metaplanet [1][3][8] - Prenetics has appointed Andy Cheung, former COO of OKEx, to its Board of Directors to provide strategic oversight for its Bitcoin treasury initiative [3][5] Financial Strategy - Prenetics has a strengthened balance sheet with over $117 million in total liquidity, including approximately $66 million in cash reserves and a debt-free balance sheet [15] - The Board has approved a majority allocation of its balance sheet to Bitcoin, demonstrating a strong commitment to digital asset adoption [9] - The company is actively discussing partnerships with leading financial institutions to develop a long-term Bitcoin acquisition plan [10] Operational Integration - Prenetics plans to accept cryptocurrency payments across its direct-to-consumer platforms, creating a seamless Bitcoin ecosystem from treasury to operations [11] - The company is implementing sophisticated alpha-generating strategies to maximize returns on its Bitcoin holdings, including yield generation and strategic lending [10] Business Growth - Prenetics has increased its full-year 2025 revenue guidance to $80-100 million, indicating confidence in its core business trajectory [12] - The company has achieved significant growth with over 55,000 customers and a 91% subscription rate across its health brands [14] Leadership and Expertise - The strategic appointment of industry leaders like Andy Cheung and Tracy Hoyos Lopez enhances Prenetics' credibility and operational guidance in the crypto space [5][13] - The company is leveraging the expertise of its advisory team to navigate the complexities of corporate Bitcoin adoption and to architect the future intersection of healthcare and digital assets [7][8]

Core Viewpoint - Prenetics Global Limited has announced the divestment of its majority stake in ACT Genomics to Delta Electronics for up to US$71.78 million, enhancing its financial position and focusing on high-growth consumer health brands [1][3][5] Financial Position - The divestment will provide Prenetics with approximately US$46 million in cash, increasing its pro-forma cash reserves to about US$86 million and pro-forma short-term assets to US$117 million, while maintaining a debt-free balance sheet [1][8][17] - Prenetics raised its FY2025 revenue outlook to US$80 – US$100 million from the previous US$73 – US$85 million, driven by the growth of its IM8 brand [5][6] Strategic Transformation - The divestment is part of Prenetics' strategic transformation to simplify its business model and enhance financial flexibility, allowing for accelerated growth in the consumer health market [3][11] - Prenetics now focuses on three consumer health brands: IM8, CircleDNA, and Europa, which are expected to synergistically enhance its market position [4][7][11] Market Performance - Prenetics' consumer health business has shown significant momentum, with Q1 2025 revenue of US$14.4 million, representing a 336.5% year-over-year increase, and a projected Q2 revenue of US$8.5 million [6][8] - The company has acquired over 55,000 customers and achieved a 91% subscription rate, indicating strong market demand [6][8] Innovation and Future Outlook - With a robust cash position, Prenetics is positioned to explore innovative treasury management strategies, including digital asset adoption and Bitcoin treasury strategies [10][11] - The company maintains a 35% stake in Insighta, valued at US$70 million, which adds significant value for shareholders [9]

[Executive Summary & Highlights](index=1&type=section&id=1.%20Executive%20Summary%20%26%20Highlights) Prenetics reported strong Q1 2025 financial performance, exceeding expectations, driven by consumer business growth and strategic realignment, with a raised full-year revenue outlook [First Quarter 2025 Financial Highlights](index=1&type=section&id=1.1%20First%20Quarter%202025%20Financial%20Highlights) Prenetics reported an exceptionally strong first quarter of 2025, with revenue from continuing operations increasing significantly and a raised full-year revenue outlook, as the consumer business, particularly IM8, demonstrated robust growth | Metric | Q1 2025 (USD) | Q1 2024 (USD) | YoY Change | | :-------------------------------------- | :------------ | :------------ | :--------- | | Revenue (continuing operations) | $17.3 million | $6.4 million | +169.9% | | Consumer Business Revenue (excl. ACT Genomics) | $14.4 million | $3.3 million | +336.5% | | Gross Profit (continuing operations) | $7.3 million | $3.8 million | +94.1% | | Adjusted EBITDA Loss (continuing operations) | $(6.5) million | $(4.1) million | +59.4% (less negative) | - Raised full-year 2025 revenue outlook to **$80 - $100 million**, up from $73 - $85 million[5](index=5&type=chunk)[7](index=7&type=chunk) - IM8 contributed **$5.7 million** in Q1 2025, with Q2 revenue projected to reach approximately **$8.5 million**, representing a **50% quarter-over-quarter increase**[5](index=5&type=chunk)[7](index=7&type=chunk) - Cash and other short-term assets totaled **$78.0 million** as of March 31, 2025, and the Company remained debt-free[7](index=7&type=chunk) [Management Commentary](index=1&type=section&id=1.2%20Management%20Commentary) CEO Danny Yeung highlighted the strong Q1 performance, exceeding expectations, and the successful strategic realignment towards global consumer healthcare, emphasizing the company's robust financial foundation and pioneering crypto strategy for treasury management and capital allocation - The first quarter of 2025 marked an exceptionally strong start for Prenetics, with financial performance that significantly surpassed expectations and strategic advancements that position us for accelerated growth[4](index=4&type=chunk) - The strategic realignment towards the global consumer healthcare market is gaining tremendous traction[5](index=5&type=chunk) - The company is actively pioneering innovative approaches to treasury management and capital allocation, strategically embracing a crypto strategy and Bitcoin adoption to optimize shareholder value and revolutionize patient care[9](index=9&type=chunk) [Business Updates and Strategic Initiatives](index=2&type=section&id=2.%20Business%20Updates%20and%20Strategic%20Initiatives) This section details Prenetics' strong IM8 business momentum, strategic crypto advisory initiatives, increased full-year revenue outlook, and the ongoing strategic review of ACT Genomics [IM8 Business Momentum](index=2&type=section&id=2.1%20IM8%20Business%20Momentum) IM8 has achieved remarkable success in its first six months since launch, attracting over 55,000 customers and expanding its global footprint to 31 countries, demonstrating strong customer loyalty and market potential - IM8 has attracted over **55,000 customers** and delivered more than **4.9 million servings** of its flagship Daily Ultimate Essentials[10](index=10&type=chunk) - Achieved an industry-leading **91% subscription rate** and an impressive average order value of **US$109**[10](index=10&type=chunk) - Shipping now extended to **31 countries worldwide**, rapidly expanding its global footprint[10](index=10&type=chunk) [Strategic Crypto Advisory Initiatives](index=2&type=section&id=2.2%20Strategic%20Crypto%20Advisory%20Initiatives) Prenetics is actively developing an innovative treasury management approach by evaluating strategic crypto initiatives and Bitcoin adoption, engaging with leading crypto industry veterans for expert guidance to optimize capital allocation and enhance shareholder value - Management is actively advancing an innovative treasury management approach by evaluating strategic crypto initiatives and Bitcoin adoption[11](index=11&type=chunk) - Engaging in active discussions with leading crypto industry veterans and thought leaders to provide expert guidance[11](index=11&type=chunk) - This forward-thinking approach aims to optimize capital allocation and drive long-term shareholder value creation[11](index=11&type=chunk) [Outlook](index=2&type=section&id=2.3%20Outlook) The company has increased its full-year 2025 revenue guidance to $80-$100 million, driven by the exceptional growth of IM8, which is projected to reach $8.5 million in Q2 revenue - Increased full-year 2025 revenue guidance to **$80 to $100 million** from the previously projected $73 to $85 million[12](index=12&type=chunk) - IM8's second quarter revenue is expected to reach approximately **$8.5 million**, representing **50% quarter-over-quarter growth**[12](index=12&type=chunk) [ACT Genomics Strategic Review](index=2&type=section&id=2.4%20ACT%20Genomics%20Strategic%20Review) Prenetics is nearing the conclusion of its strategic review of ACT Genomics and expects to announce a decision regarding its ownership stake shortly - Significant progress has been made in the previously announced strategic review of ACT Genomics[8](index=8&type=chunk) - An announcement regarding the strategic decision on the ownership stake in ACT Genomics will be forthcoming[8](index=8&type=chunk) [Company Information](index=3&type=section&id=3.%20Company%20Information) This section provides an overview of Prenetics as a health sciences company and details about its premium core nutrition brand, IM8, co-founded by David Beckham [About Prenetics](index=3&type=section&id=3.1%20About%20Prenetics) Prenetics is a leading health sciences company focused on advancing consumer and clinical health, with key consumer initiatives including IM8 and Europa, aiming to enhance life through science - Prenetics (NASDAQ:PRE) is a leading health sciences company dedicated to advancing consumer and clinical health[13](index=13&type=chunk) - Consumer initiatives are led by IM8, a health and wellness brand, and Europa, one of the largest sports distribution companies in the USA[13](index=13&type=chunk) - The company's commitment is to 'enhancing life through science'[13](index=13&type=chunk) [About IM8](index=3&type=section&id=3.2%20About%20IM8) IM8 is a premium core nutrition brand, co-founded by David Beckham, offering science-backed health solutions, with its flagship product, Daily Ultimate Essentials, being an all-in-one powder supplement certified for sport and free from common allergens - IM8 is a premium core nutrition brand, born from a collaboration with David Beckham as a co-founding partner and an elite team of scientists[14](index=14&type=chunk) - Its flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement engineered to replace 16 different supplements[14](index=14&type=chunk) - The product is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners[14](index=14&type=chunk) [Financial Information](index=3&type=section&id=4.%20Financial%20Information) This section outlines the basis of financial presentation, provides unaudited consolidated financial statements, reconciliations of non-IFRS measures, and notes to the financial statements [Basis of Presentation & Non-IFRS Financial Measures Explanation](index=3&type=section&id=4.1%20Basis%20of%20Presentation%20%26%20Non-IFRS%20Financial%20Measures%20Explanation) This section explains the basis of presentation for financial statements, including the use and definition of non-IFRS financial measures like Adjusted EBITDA, clarifying that these measures supplement IFRS, are not standardized, and have limitations, encouraging investors to review reconciliations - Non-IFRS measures provided include adjusted EBITDA loss from continuing operations, total revenue from continuing operations (normalized to exclude ACT Genomics), and total adjusted EBITDA from continuing operations (normalized to exclude ACT Genomics)[17](index=17&type=chunk) - These non-IFRS measures are not based on any standardized methodology prescribed by IFRS and are not necessarily comparable to similarly-titled measures presented by other companies[17](index=17&type=chunk) - Adjusted EBITDA is derived from loss for the period by excluding various non-cash and/or non-recurring items such as depreciation, amortization, interest income, income tax credit, share-based payment expenses, and fair value adjustments[6](index=6&type=chunk)[18](index=18&type=chunk) [Unaudited Consolidated Statements of Financial Position (Balance Sheet)](index=5&type=section&id=4.2%20Unaudited%20Consolidated%20Statements%20of%20Financial%20Position%20(Balance%20Sheet)) The unaudited consolidated balance sheet as of March 31, 2025, shows a slight decrease in total assets and total equity compared to December 31, 2024, while total liabilities increased marginally | Metric | March 31, 2025 (USD thousands) | December 31, 2024 (USD thousands) | Change | | :-------------------------------- | :----------------------------- | :------------------------------ | :----- | | Total Assets | 204,015 | 213,575 | (9,560) | | Current Assets | 78,024 | 86,148 | (8,124) | | Cash and Cash Equivalents | 47,966 | 52,251 | (4,285) | | Total Liabilities | 42,899 | 42,229 | 670 | | Total Equity | 161,116 | 171,346 | (10,230) | [Unaudited Consolidated Statements of Profit or Loss and Other Comprehensive Income (Income Statement)](index=6&type=section&id=4.3%20Unaudited%20Consolidated%20Statements%20of%20Profit%20or%20Loss%20and%20Other%20Comprehensive%20Income%20(Income%20Statement)) For Q1 2025, Prenetics reported a significant increase in revenue from continuing operations and gross profit compared to Q1 2024, but also an increased operating loss and net loss for the period | Metric | Q1 2025 (USD thousands) | Q1 2024 (USD thousands) | YoY Change | | :-------------------------------------- | :---------------------- | :---------------------- | :--------- | | Revenue (Continuing Operations) | 17,312 | 6,413 | +169.9% | | Direct Costs | (9,970) | (2,631) | +279.0% | | Gross Profit | 7,342 | 3,782 | +94.1% | | Operating Loss (Continuing Operations) | (10,632) | (9,160) | +16.1% (larger loss) | | Loss for the Period | (11,016) | (9,052) | +21.7% (larger loss) | | Basic Loss per Share | (0.80) | (0.70) | +14.3% (larger loss) | [Unaudited Non-IFRS Financial Measures Reconciliation](index=7&type=section&id=4.4%20Unaudited%20Non-IFRS%20Financial%20Measures%20Reconciliation) This section provides reconciliations for non-IFRS measures, showing an adjusted EBITDA loss from continuing operations of $(6.5) million for Q1 2025, and a normalized revenue (excluding ACT Genomics) of $14.4 million, with a corresponding normalized adjusted EBITDA loss of $(4.8) million | Metric | Q1 2025 (USD thousands) | Q4 2024 (USD thousands) | Q1 2024 (USD thousands) | | :---------------------------------------------------- | :---------------------- | :---------------------- | :---------------------- | | Adjusted EBITDA from continuing operations (Non-IFRS) | (6,545) | (9,414) | (4,106) | | Revenue normalized to exclude ACT Genomics (non-GAAP) | 14,411 | 6,563 | 3,301 | | Adjusted EBITDA normalized to exclude ACT Genomics (non-GAAP) | (4,763) | (7,448) | (2,129) | [Notes to Financial Statements](index=8&type=section&id=4.5%20Notes%20to%20Financial%20Statements) This section provides additional context for specific financial line items, including the nature of liabilities for puttable financial instruments related to ACT Genomics acquisition and the classification of COVID-19 testing and EMEA DNA testing operations as discontinued - Liabilities for puttable financial instrument arise from put options granted to remaining shareholders of ACT Genomics, valued at the present value of the exercise price[23](index=23&type=chunk) - The COVID-19 testing business (ceased Q2 2023) and other DNA testing operations in the EMEA regions (ceased Q4 2023) are reported as discontinued operations under IFRS 5[23](index=23&type=chunk) Employee Equity-Settled Share-Based Payment Expenses | Expense Category | Q1 2025 (USD) | Q4 2024 (USD) | Q1 2024 (USD) | | :------------------------------- | :---------- | :---------- | :---------- | | Direct costs | — | 39 | 1 | | Selling and distribution expenses | 1 | 153 | 1 | | Research and development expenses | 467 | 511 | 758 | | Administrative and other operating expenses | 390 | 2,049 | 1,156 | | **Total** | **858** | **2,752** | **1,916** | [Legal & Disclosure](index=3&type=section&id=5.%20Legal%20%26%20Disclosure) This section includes cautionary forward-looking statements and provides contact information for investor relations inquiries [Forward-Looking Statements](index=3&type=section&id=5.1%20Forward-Looking%20Statements) This section contains standard cautionary language regarding forward-looking statements, noting they are based on estimates and forecasts, involve inherent risks and uncertainties, and actual results may differ materially, with the company not undertaking to update this information - Statements are forward-looking, made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995, covering goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, and growth opportunities[15](index=15&type=chunk) - Forward-looking statements are based upon estimates and forecasts, reflecting views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties[15](index=15&type=chunk) - A number of factors could cause actual results to differ materially, including the Company's ability to develop and grow its business, execute new strategies, results of studies/trials, and M&A opportunities[15](index=15&type=chunk) [Investor Relations Contact](index=3&type=section&id=5.2%20Investor%20Relations%20Contact) Provides contact information for investor relations inquiries - Investor Relations contact emails: investors@prenetics.com, PRE@mzgroup.us, angela.hm.cheung@prenetics.com[15](index=15&type=chunk) - Contact person: Angela Cheung, Investor Relations / Corporate Finance, Prenetics Global Limited[15](index=15&type=chunk)

Core Insights - Prenetics Global Limited reported a strong financial performance for Q1 2025, with revenue increasing by 336.5% year-over-year to $14.4 million, excluding ACT Genomics [3][7] - The company raised its full-year revenue outlook from $73 - $85 million to $80 - $100 million, reflecting accelerating momentum across its business units [4][13] - Prenetics has a robust cash position of $78 million, allowing for continued innovation and strategic initiatives, including a focus on cryptocurrency and Bitcoin adoption [6][12] Financial Highlights - Revenue from continuing operations was $17.3 million in Q1 2025, a 169.9% increase compared to Q1 2024 [7] - Gross profit from continuing operations reached $7.3 million, up 94.1% year-over-year [7] - Adjusted EBITDA loss from continuing operations was $(6.5) million, an increase of 59.4% compared to the previous year [7] Business Updates - The IM8 brand contributed $5.7 million in revenue for Q1 2025, with expectations of approximately $8.5 million in Q2, representing a 50% quarter-over-quarter increase [4][13] - IM8 has over 55,000 customers and has delivered more than 4.9 million servings of its flagship product [11] - The strategic review of ACT Genomics is nearing conclusion, with an announcement regarding ownership stake expected soon [5] Strategic Initiatives - The company is actively pursuing innovative treasury management approaches, including discussions on digital asset opportunities and Bitcoin adoption [6][12] - Prenetics aims to leverage its strong cash position to enhance its competitive positioning in the health tech sector through strategic crypto initiatives [6][12]

Core Viewpoint - Broad Arrow Auctions, a subsidiary of Hagerty, is set to host its inaugural Concorso d'Eleganza Villa d'Este Auction on May 24-25, 2025, featuring over 70 collectible classic cars, including significant historical models like the Ferrari 166 Spyder Corsa and the 1938 Talbot-Lago T150 C Spéciale Teardrop Coupé [1][2][3]. Company Overview - Broad Arrow Auctions is a leading global collector car auction house, founded in 2021, and has quickly become the fastest-growing auction house in its segment [28]. - The company is expanding its global footprint, with its first European auction taking place in May 2025 as the official auction house for the Concorso d'Eleganza Villa d'Este in Italy [28]. Auction Highlights - The auction will feature the first-ever public sale of the Ferrari 166 Spyder Corsa by Ansaloni, estimated between €5.5 million and €7.5 million, which is recognized as Enzo Ferrari's first customer competition car [10][11][13]. - Another highlight is the 1938 Talbot-Lago T150 C Spéciale Teardrop Coupé, estimated between €4.5 million and €6.5 million, known for its unique design and historical significance [4][9]. - Additional notable cars include the 1949 Talbot-Lago T26 Grand Sport Coupe, estimated at €1.2 million to €1.5 million, and the 1936 Maserati 6CM Factory Works, estimated at €850,000 to €950,000 [9][23]. Event Details - The auction will take place at Villa Erba, located on the shores of Lake Como, and is expected to attract renowned collectors seeking to enhance their collections with some of the most desirable classic automobiles [25][26].